We understand that it can be challenging to gain clarity and perspective on breaking Parkinson's news. Q&As in this section are conducted with leading experts in the Parkinson's disease research field to quickly provide an informed, impartial opinion on new findings -- and to get to the bottom of what they might mean for researchers and people living with PD today.
September 19, 2008
On Thursday, September 17, 2008, news media around the world reported on the role of a mutation in the gene LRRK2 in Parkinson's disease. The reports were prompted by the revelation by Google co-founder Sergey Brin that he and his mother, who lives with PD, both are carriers of the mutation.
To help patients interpret the news and its potential relevance to their own PD and treatment, The Michael J. Fox Foundation's Research team has assembled answers to fundamental questions on the field's cur...Read More
July 10, 2008
In the first week of July 2008, Titan Pharmaceuticals, Inc., announced disappointing results from the Phase 2 trial of its symptomatic Parkinson's therapy Spheramine. The announcement came in the wake of results showing that the experimental drug had failed to meet clinical endpoints outlined for the trial. Only one week earlier, the company had reported positive five-year data from its Phase 1 open-label trial of the same treatment.
The Michael J. Fox Foundation spoke with David Standaert, MD,...Read More
June 18, 2008
UPDATE, JULY 14, 2008: Teva has announced plans to report top-line data from the ADAGIO Study at the 12th Congress of European Federation of Neurological Societies (EFNS) on August 26, 2008 in Madrid, Spain.
On Monday, June 16, 2008, Israeli drugmaker Teva issued a press release reporting that Azilect (rasagiline) was on track to become the first disease-modifying treatment for Parkinson's disease. The company has completed the ADAGIO Phase 3 clinical trial, in which Azilect tablets met thre...
Common High Blood Pressure Treatment Seems to Reduce Risk of Parkinson's Disease: What Does It Mean for PD Patients?
February 22, 2008
During the week of February 11, 2008, news media all over the world reported on a study showing that a widely used, FDA-approved high blood pressure medication -- a class of drugs known as calcium channel blockers -- seems to reduce the risk of Parkinson's disease. Independently, D. James Surmeier, PhD, professor and chair of the Department of Physiology at the Feinberg School of Medicine and director of the Morris K. Udall Center of Research Excellence for Parkinson's Disease of Northwestern Un...Read More